Streetbeat News

PODD

Insulet Corporation

https://www.insulet.com

Industry

Medical - Devices

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Open

259.39

Mkt cap

18B

Volume

428K

High

265.26

P/E Ratio

44.56

52-wk high

279.40

Low

259.18

Div yield

N/A

52-wk low

160.19

Insulet has updated its revenue growth expectations for Q2 and the full year of 2024, indicating an increase in projected revenues across its product lines, especially in the Omnipod range. The company now expects Q2 revenue growth of 15%-18% and has raised its full-year 2024 revenue growth forecast to 14%-18%. Notably, the International Omnipod product line's growth expectations have been significantly increased from 7%-10% to 12%-15%. However, the Drug Delivery product line is expected to see a significant decline. Gross and operating margin guidance for 2024 has also been updated, with operating margins expected to increase slightly.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:13 pm

Insulet (NASDAQ:PODD) reported Q1 earnings of $0.73 per share, surpassing the $0.39 estimate, marking an 87.18% beat and a 217.39% increase from last year. Sales reached $441.70M, exceeding the $424.05M estimate by 4.16% and showing a 23.35% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 8:03 pm

Today's session highlighted significant options activity in the Health Care sector, with notable trades on stocks like MRNA, ALNY, HUM, MCK, CORT, NVO, BMY, THC, BLUE, and PODD. The activity ranged from bullish to bearish sentiments, involving both call and put options with various expiration dates and strike prices. This options activity could indicate upcoming trading opportunities based on the whales' movements.

Portfolio Pulse from Benzinga Insights

May 09, 2024 | 5:35 pm

Insulet shares are trading higher following an upgrade by Wolfe Research from Peer Perform to Outperform.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 1:26 pm

Four analysts have recently updated their ratings on Insulet (NASDAQ:PODD), showing a mix of bullish and indifferent stances, with three somewhat bullish and one indifferent rating in the last 30 days. The average 12-month price target for Insulet is now $217.00, with a high estimate of $230.00 and a low estimate of $200.00, marking a slight decrease of 0.46% in the average price target. Insulet's financial performance includes a revenue growth rate of 37.9%, a net margin of 20.26%, an ROE of 15.42%, and an ROA of 4.09%, indicating strong profitability and financial health despite a high debt-to-equity ratio of 1.93.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 1:00 pm

Wolfe Research analyst Mike Polark upgraded Insulet (NASDAQ:PODD) from Peer Perform to Outperform and set a $200 price target.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 9:37 am

Insulet announced the appointment of Ana Maria Chadwick as Executive Vice President, Chief Financial Officer, and Treasurer, effective April 22, 2024. This strategic move could signal a new direction in financial strategy and management for the company.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 10:01 am

Insulet announced it will present results from its first Omnipod 5 Randomized Controlled Trial (OP5-003) at the International Conference on Advanced Technologies & Treatments for Diabetes. This marks a significant milestone for the company as it showcases the effectiveness and advancements of its Omnipod 5 product.

Portfolio Pulse from Benzinga Newsdesk

March 05, 2024 | 11:04 am

In the first two months of 2024, Nvidia Corp. led S&P 500 stocks with a 60% gain, but other stocks also saw significant returns. The S&P 500 Equal Weight ETF (RSP) and SPDR S&P 500 ETF Trust (SPY) posted gains of 3% and 7%, respectively. Top performers included Constellation Energy, Meta Platforms, and Advanced Micro Devices, among others. Wall Street analysts see upside potential in stocks like Uber Technologies and Catalent. The VanEck Social Sentiment ETF (BUZZ) highlights stocks favored by social media, including Coinbase and MicroStrategy.

Portfolio Pulse from Piero Cingari

February 29, 2024 | 9:58 pm

Insulet (PODD) provided its Q1 2024 and FY24 revenue growth guidance, expecting 17%-20% and 12%-17% growth respectively. The guidance accounts for a $20M-$25M shift in U.S. revenue due to accelerated pharmacy wholesaler orders ahead of a new ERP system implementation. Product line growth forecasts include a significant increase in Drug Delivery for Q1 2024. Gross margin is projected at 68%-69%, and operating margin at 13% for FY24, excluding a 60 basis point negative impact from the revenue shift.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 8:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.